Salivary gland carcinomas

Oral and Maxillofacial Surgery

Volumn 16, Issue 3, 2012, Pages 267-283

  Ettl, Tobias ^a   Schwarz Furlan, Stephan ^b   Gosau, Martin ^a   Reichert, Torsten E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Diagnostics; Genetics; Histology; Prognosis; Salivary gland carcinomas; Therapy

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; CHROMOSOME ABERRATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MULTIMODAL IMAGING; NECK DISSECTION; PAROTID GLAND TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTOR; SALIVARY GLAND; SALIVARY GLAND TUMOR; SURGICAL FLAPS;

BIOPSY; CHEMORADIOTHERAPY, ADJUVANT; CHROMOSOME ABERRATIONS; DIFFUSION MAGNETIC RESONANCE IMAGING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MULTIMODAL IMAGING; NECK DISSECTION; NEOPLASM GRADING; NEOPLASM STAGING; PAROTID NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; SURGICAL FLAPS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84865808681     PISSN: 18651550     EISSN: 18651569     Source Type: Journal    
DOI: 10.1007/s10006-012-0350-9     Document Type: Article

References (192)

1. Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon.
2. Eveson JW, Auclair P, Gnepp DR, El-Naggar AK (2005) Tumours of the salivary glands: introduction. In: Barnes L, Eveson JW, Reichart PDS (eds) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon, pp 212-215.
3. Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18: 2899-2906.
4. Kakarala K, Bhattacharyya N (2010) Survival in oral cavity minor salivary gland carcinoma. Otolaryngol Head Neck Surg 143: 122-126.
5. Tian Z, Wang L, Hu Y, Li J (2010) Salivary gland neoplasm in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39: 235-242.
6. Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A (2011) Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck 33: 1476-1481.
7. Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2, 807 patients. Head Neck Surg 8: 177-184.
8. Eveson JW, Cawson RA (1985) Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146: 51-58.
9. Ellis GL, Auclair PL (1996) Tumours of the salivary glands. Armed Forces Institute of Pathology, Washington.
10. Ostman J, Anneroth G, Gustafsson H, Tavelin B (1997) Malignant salivary gland tumours in Sweden 1960-1989-an epidemiological study. Oral Oncol 33: 169-176.
11. Renehan AG, Gleave EN, Slevin NJ, McGurk M (1999) Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 80: 1296-1300.
12. Bjorndal K, Krogdahl A, Therkildsen MH et al (2011) Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47: 677-682.
13. Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS (1998) Salivary gland carcinomas-prognostic factors. Acta Oncol 37: 701-713.
14. Terhaard CH, Lubsen H, van der Tweel I et al (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26: 681-692, discussion 692-683.
15. Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11; 19) translocation. Histopathology 58: 557-570.
16. Kupferman ME, de la Garza GO, Santillan AA et al (2010) Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol 17: 3301-3307.
17. Boukheris H, Ron E, Dores GM, Stovall M, Smith SA, Curtis RE (2008) Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 113: 3153-3159.
18. Land CE, Saku T, Hayashi Y et al (1996) Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. Radiat Res 146: 28-36.
19. Sadetzki S, Oberman B, Mandelzweig L et al (2008) Smoking and risk of parotid gland tumors: a nationwide case-control study. Cancer 112: 1974-1982.
20. Goldstein AM, Yuen J, Tucker MA (1997) Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8: 865-871.
21. Horn-Ross PL, Ljung BM, Morrow M (1997) Environmental factors and the risk of salivary gland cancer. Epidemiology 8: 414-419.
22. Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24: 579-586.
23. Nasser SM, Faquin WC, Dayal Y (2003) Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119: 801-806.
24. Schwarz-Furlan S, Brase C, Stockmann P, Furlan I, Hartmann A (2010) Hereditary head and neck tumors. Der Pathologe 31: 477-484.
25. O'Neill ID (2009) t(11; 19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma. Oral Oncol 45: 2-9.
26. Tonon G, Modi S, Wu L et al (2003) t(11; 19)(q21; p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33: 208-213.
27. Miyabe S, Okabe M, Nagatsuka H et al (2009) Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg 67: 1432-1441.
28. Nakayama T, Miyabe S, Okabe M et al (2009) Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 22: 1575-1581.
29. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN (2010) A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol 34: 1106-1121.
30. Persson F, Andren Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosom Cancer 48: 69-82.
31. Fehr A, Stenman G, Bullerdiek J, Loning T (2009) Molecular markers in salivary gland tumors: their use in diagnostic and prognostic workup. Der Pathologe 30: 466-471.
32. Mitani Y, Li J, Rao PH et al (2011) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16: 4722-4731.
33. Mitani Y, Rao PH, Futreal PA et al (2010) Novel chromosomal rearrangements and break points at the t(6; 9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 17: 7003-7014.
34. Rao PH, Roberts D, Zhao YJ et al (2008) Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 14: 5181-5187.
35. Skalova A, Vanecek T, Sima R et al (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34: 599-608.
36. Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I (2012) Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol 36: 27-34.
37. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53: 567-577.
38. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16: 2266-2274.
39. Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103: 510-516.
40. Ettl T, Stiegler C, Zeitler K et al (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43: 921-931.
41. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12: 956-960.
42. Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154: 107-111.
43. Sorensen KB, Godballe C, de Stricker K, Krogdahl A (2006) Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 35: 286-291.
44. Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106: 719-726.
45. Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
46. De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
47. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
48. Pandolfi PP (2004) Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337-2338.
49. Negri FV, Bozzetti C, Lagrasta CA et al (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102: 162-164.
50. Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C (2010) Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res 70: 9143-9152.
51. Ettl T, Schwarz-Furlan S, Haubner F, et al (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. doi: 10. 1016/j. oraloncology. 2012. 02. 021.
52. Durr ML, Mydlarz WK, Shao C et al (2010) Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One 5: e10828.
53. Schache AG, Hall G, Woolgar JA et al (2010) Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer 103: 1846-1851.
54. Williams MD, Chakravarti N, Kies MS et al (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12: 7353-7358.
55. Cheuk W, Chan JK, Ngan RK (1999) Dedifferentiation in adenoid cystic carcinoma of salivary gland: an uncommon complication associated with an accelerated clinical course. Am J Surg Pathol 23: 465-472.
56. Seethala RR, Cieply K, Barnes EL, Dacic S (2011) Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch Pathol Lab Med 135: 123-130.
57. Cheuk W, Chan JK (2007) Advances in salivary gland pathology. Histopathology 51: 1-20.
58. Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR (1999) National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck 21: 297-309.
59. Lewis JE, Olsen KD, Weiland LH (1991) Acinic cell carcinoma. Clinicopathologic review. Cancer 67: 172-179.
60. Gomez DR, Katabi N, Zhung J et al (2009) Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer 115: 2128-2137.
61. Skalova A, Sima R, Vanecek T et al (2009) Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol 33: 1137-1145.
62. Schwarz S, Zenk J, Mueller M et al (2012) The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology. doi: 10. 1111/j. 1365-2559. 2012. 04233. x.
63. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74: 134-148.
64. Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32: 596-604.
65. Seethala RR (2009) An update on grading of salivary gland carcinomas. Head Neck Pathol 3: 69-77.
66. Weiler C, Zengel P, van der Wal JE et al (2010) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59: 741-750.
67. Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 110: 172-176.
68. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P (1994) Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 78: 64-73.
69. McHugh JB, Visscher DW, Barnes EL (2009) Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133: 1763-1774.
70. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103: 2526-2533.
71. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77: 223-230.
72. Skalova A, Starek I, Vanecek T et al (2003) Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42: 348-356.
73. Schwarz S, Muller M, Ettl T, Stockmann P, Zenk J, Agaimy A (2011) Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Int J Clin Exp Pathol 4: 336-348.
74. Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP (1999) Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 86: 207-219.
75. Evans HL, Luna MA (2000) Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol 24: 1319-1328.
76. Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18: 29-45.
77. Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25: 835-845.
78. Auclair PL, Goode RK, Ellis GL (1992) Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer 69: 2021-2030.
79. Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23: 705-712.
80. Jouzdani E, Yachouh J, Costes V et al (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46: 323-331.
81. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) American Joint Committee on Cancer: AJCC cancer staging manual. Springer, New York.
82. Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM: classification of malignant tumours (UICC International Union Against Cancer). Wiley, New York.
83. Terhaard C, Lubsen H, Tan B et al (2006) Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 42: 2744-2750.
84. Eneroth CM (1972) Facial nerve paralysis. A criterion of malignancy in parotid tumors. Arch Otolaryngol 95: 300-304.
85. Lee YY, Wong KT, King AD, Ahuja AT (2008) Imaging of salivary gland tumours. Eur J Radiol 66: 419-436.
86. Gritzmann N, Rettenbacher T, Hollerweger A, Macheiner P, Hubner E (2003) Sonography of the salivary glands. Eur Radiol 13: 964-975.
87. Kovacevic DO, Fabijanic I (2010) Sonographic diagnosis of parotid gland lesions: correlation with the results of sonographically guided fine-needle aspiration biopsy. J Clin Ultrasound 38: 294-298.
88. Burke CJ, Thomas RH, Howlett D (2011) Imaging the major salivary glands. Br J Oral Maxillofac Surg 49: 261-269.
89. Freling NJ, Molenaar WM, Vermey A et al (1992) Malignant parotid tumors: clinical use of MR imaging and histologic correlation. Radiology 185: 691-696.
90. Wittekindt C, Burmeister HP, Guntinas-Lichius O (2009) Diagnostic and therapy of salivary gland diseases: relevant aspects for the pathologist from the clinical perspective. Der Pathologe 30: 424-431.
91. Eida S, Sumi M, Nakamura T (2010) Multiparametric magnetic resonance imaging for the differentiation between benign and malignant salivary gland tumors. J Magn Reson Imaging 31: 673-679.
92. Habermann CR, Arndt C, Graessner J et al (2009) Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? Ajnr 30: 591-596.
93. Takashima S, Noguchi Y, Okumura T, Aruga H, Kobayashi T (1993) Dynamic MR imaging in the head and neck. Radiology 189: 813-821.
94. Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M (2003) Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology 226: 345-354.
95. Hanna E, Vural E, Prokopakis E, Carrau R, Snyderman C, Weissman J (2007) The sensitivity and specificity of high-resolution imaging in evaluating perineural spread of adenoid cystic carcinoma to the skull base. Arch Otolaryngol Head Neck Surg 133: 541-545.
96. Roh JL, Ryu CH, Choi SH et al (2007) Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48: 240-246.
97. Jeong HS, Chung MK, Son YI et al (2007) Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med 48: 1237-1244.
98. Keyes JW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF (1994) Salivary gland tumors: pretherapy evaluation with PET. Radiology 192: 99-102.
99. Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL (2010) Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 120: 734-738.
100. Branstetter BF 4th, Blodgett TM, Zimmer LA et al (2005) Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 235: 580-586.
101. Kechagias N, Ntomouchtsis A, Valeri R et al (2012) Fine-needle aspiration cytology of salivary gland tumours: a 10-year retrospective analysis. Oral Maxillofac Surg 16: 35-40.
102. Schmidt RL, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin Pathol 136: 45-59.
103. Christensen RK, Bjorndal K, Godballe C, Krogdahl A (2010) Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 32: 104-108.
104. Colella G, Cannavale R, Flamminio F, Foschini MP (2010) Fine-needle aspiration cytology of salivary gland lesions: a systematic review. J Oral Maxillofac Surg 68: 2146-2153.
105. Salgarelli AC, Cappare P, Bellini P, Collini M (2009) Usefulness of fine-needle aspiration in parotid diagnostics. Oral Maxillofac Surg 13: 185-190.
106. Schmidt RL, Hall BJ, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of ultrasound-guided core needle biopsy for salivary gland lesions. Am J Clin Pathol 136: 516-526.
107. Howlett DC, Menezes LJ, Lewis K, Moody AB, Violaris N, Williams MD (2007) Sonographically guided core biopsy of a parotid mass. Ajr 188: 223-227.
108. Seethala RR, LiVolsi VA, Baloch ZW (2005) Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head Neck 27: 217-223.
109. Zbaren P, Guelat D, Loosli H, Stauffer E (2008) Parotid tumors: fine-needle aspiration and/or frozen section. Otolaryngol Head Neck Surg 139: 811-815.
110. Schmidt RL, Hunt JP, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of frozen section for parotid gland lesions. Am J Clin Pathol 136: 729-738.
111. Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS (2007) Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 133: 546-550.
112. Mallik S, Agarwal J, Gupta T et al (2010) Prognostic factors and outcome analysis of submandibular gland cancer: a clinical audit. J Oral Maxillofac Surg 68: 2104-2110.
113. Rinaldo A, Shaha AR, Pellitteri PK, Bradley PJ, Ferlito A (2004) Management of malignant sublingual salivary gland tumors. Oral Oncol 40: 2-5.
114. Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q (2010) The treatment of sublingual gland tumours. Int J Oral Maxillofac Surg 39: 863-868.
115. Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E (2004) Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 114: 949-956.
116. Spiro JD, Spiro RH (2003) Salivary gland neoplasms. In: Evans PHR, Mongomery PQ, Gullane PJ (eds) Principles and practice of head and neck oncology. MD Martin Dunitz, London, pp 385-403.
117. Papadogeorgakis N, Goutzanis L, Petsinis V, Alexandridis C (2012) Management of malignant parotid tumors. Oral Maxillofac Surg 16: 29-34.
118. Eisele DW, Wang SJ, Orloff LA (2010) Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 32: 399-405.
119. Lim YC, Lee SY, Kim K et al (2005) Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 41: 1021-1027.
120. Spiro JD, Spiro RH (2003) Cancer of the parotid gland: role of 7th nerve preservation. World J Surg 27: 863-867.
121. Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13: 7-16.
122. Carrillo JF, Vazquez R, Ramirez-Ortega MC, Cano A, Ochoa-Carrillo FJ, Onate-Ocana LF (2007) Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 109: 2043-2051.
123. Domenick NA, Johnson JT (2011) Parotid tumor size predicts proximity to the facial nerve. Laryngoscope 121: 2366-2370.
124. Sanabria A, Kowalski LP, Bradley PJ et al (2012) Sternocleidomastoid muscle flap in preventing Frey's syndrome after parotidectomy: a systematic review. Head Neck 34: 589-598.
125. Curry JM, Fisher KW, Heffelfinger RN, Rosen MR, Keane WM, Pribitkin EA (2008) Superficial musculoaponeurotic system elevation and fat graft reconstruction after superficial parotidectomy. Laryngoscope 118: 210-215.
126. Filho WQ, Dedivitis RA, Rapoport A, Guimaraes AV (2004) Sternocleidomastoid muscle flap preventing Frey syndrome following parotidectomy. World J Surg 28: 361-364.
127. de Bree R, van der Waal I, Leemans CR (2007) Management of Frey syndrome. Head Neck 29: 773-778.
128. Cannady SB, Seth R, Fritz MA, Alam DS, Wax MK (2010) Total parotidectomy defect reconstruction using the buried free flap. Otolaryngol Head Neck Surg 143: 637-643.
129. Elliott RM, Weinstein GS, Low DW, Wu LC (2011) Reconstruction of complex total parotidectomy defects using the free anterolateral thigh flap: a classification system and algorithm. Ann Plast Surg 66: 429-437.
130. Nolte D, Gollmitzer I, Loeffelbein DJ, Holzle F, Wolff KD (2004) Botulinum toxin for treatment of gustatory sweating. A prospective randomized study. Mund Kiefer Gesichtschir 8: 369-375.
131. Bhattacharyya N, Fried MP (2002) Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 128: 904-908.
132. Spiro RH, Armstrong J, Harrison L, Geller NL, Lin SY, Strong EW (1989) Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg 115: 316-321.
133. Armstrong JG, Harrison LB, Thaler HT et al (1992) The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69: 615-619.
134. Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F (1995) Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. Eur Arch Otorhinolaryngol 252: 139-142.
135. Zbaren P, Schupbach J, Nuyens M, Stauffer E, Greiner R, Hausler R (2003) Carcinoma of the parotid gland. Am J Surg 186: 57-62.
136. Bhattacharyya N (2004) Survival and prognosis for cancer of the submandibular gland. J Oral Maxillofac Surg 62: 427-430.
137. Bhattacharyya N, Fried MP (2005) Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 26: 39-44.
138. Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH (2010) A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys 76: 169-175.
139. Schramm VL Jr, Imola MJ (2001) Management of nasopharyngeal salivary gland malignancy. Laryngoscope 111: 1533-1544.
140. Medina JE (1998) Neck dissection in the treatment of cancer of major salivary glands. Otolaryngol Clin North Am 31: 815-822.
141. Chisholm EJ, Elmiyeh B, Dwivedi RC et al (2010) Anatomic distribution of cervical lymph node spread in parotid carcinoma. Head Neck 33: 513-515.
142. Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134: 536-538.
143. Ferlito A, Shaha AR, Rinaldo A, Mondin V (2001) Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland. ORL J Otorhinolaryngol Relat Spec 63: 123-126.
144. Stennert E, Kisner D, Jungehuelsing M et al (2003) High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 129: 720-723.
145. Valstar MH, van den Brekel MW, Smeele LE (2010) Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head Neck 32: 1402-1411.
146. Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H (2010) Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution's 20-year experience. Acta Otolaryngol 130: 286-292.
147. Ziglinas P, Arnold A, Arnold M, Zbaren P (2010) Primary tumors of the submandibular glands: a retrospective study based on 41 cases. Oral Oncol 46: 287-291.
148. Terhaard CH, Lubsen H, Rasch CR et al (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61: 103-111.
149. Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK (2001) Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 51: 952-958.
150. Chen AM, Garcia J, Granchi P, Bucci MK, Lee NY (2009) Base of skull recurrences after treatment of salivary gland cancer with perineural invasion reduced by postoperative radiotherapy. Clin Otolaryngol 34: 539-545.
151. Douglas JG, Laramore GE, Austin-Seymour M et al (1996) Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys 36: 87-93.
152. Griffin TW, Pajak TF, Laramore GE et al (1988) Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 15: 1085-1090.
153. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116: 290-293.
154. Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37: 79-85.
155. Noh JM, Ahn YC, Nam H et al (2010) Treatment results of major salivary gland cancer by surgery with or without postoperative radiation therapy. Clin Exp Otorhinolaryngol 3: 96-101.
156. Schoenfeld JD, Sher DJ, Norris CM Jr et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82: 308-314.
157. Pederson AW, Salama JK, Haraf DJ et al (2011) Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 3: 31.
158. Wang CC, Goodman M (1991) Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21: 569-576.
159. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK (2006) Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 66: 1044-1050.
160. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103: 2544-2550.
161. Laramore GE, Krall JM, Griffin TW et al (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27: 235-240.
162. Papaspyrou G, Hoch S, Rinaldo A et al (2010) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33: 905-911.
163. Rizk S, Robert A, Vandenhooft A, Airoldi M, Kornek G, Machiels JP (2007) Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol 264: 587-594.
164. Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7: 640-642.
165. Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24: 2673-2678.
166. Gilbert J, Li Y, Pinto HA et al (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28: 197-204.
167. Laurie SA, Siu LL, Winquist E et al (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116: 362-368.
168. Verweij J, de Mulder PH, de Graeff A et al (1996) Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 7: 867-869.
169. Vermorken JB, Verweij J, de Mulder PH et al (1993) Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 4: 785-788.
170. Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91: 541-547.
171. Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39: 724-727.
172. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies MS (2005) Phase II trial on gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 23: 5532.
173. Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23: 585-590.
174. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43: 33-36.
175. Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978-3984.
176. Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45: 574-578.
177. Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31: 1006-1012.
178. Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 100: 623-625.
179. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
180. Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29: e727-e730.
181. Speight PM, Barrett AW (2009) Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg 47: 587-593.
182. Cheung MC, Franzmann E, Sola JE, Pincus DJ, Koniaris LG (2010) A comprehensive analysis of parotid and salivary gland cancer: worse outcomes for male gender. J Surg Res 171: 151-158.
183. van der Schroeff MP, Terhaard CH, Wieringa MH, Datema FR, Baatenburg de Jong RJ (2010) Cytology and histology have limited added value in prognostic models for salivary gland carcinomas. Oral Oncol 46: 662-666.
184. Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85: 2255-2264.
185. Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85: 2057-2067.
186. Ettl T, Schwarz S, Kuhnel T, Stockmann P, Reichert TE, Driemel O (2008) Prognostic value of immunohistochemistry in salivary gland cancer. HNO 56: 231-238.
187. Bjorndal K, Krogdahl A, Therkildsen MH et al (2012) Salivary gland carcinoma in Denmark 1990-2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 48: 179-185.
188. Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E (1995) p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75: 2037-2044.
189. Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 44: 563-570.
190. Sequeiros-Santiago G, Garcia-Carracedo D, Fresno MF, Suarez C, Rodrigo JP, Gonzalez MV (2009) Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep 21: 1215-1222.
191. Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A (2010) High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology 56: 883-892.
192. Stenner M, Weinell A, Ponert T et al (2010) Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. Histopathology 57: 699-706.